| Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. | |
| | |
MedLine Citation:
|
PMID: 22268182 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: The purpose of this study was to investigate with immunohistochemical validation whether dynamic contrast-enhanced MRI with small-molecule contrast medium is useful for monitoring the effects of the multikinase inhibitor sorafenib on prostate carcinomas in rats. MATERIALS AND METHODS: Copenhagen rats (n = 20) into which prostate carcinoma (MAT-Ly-Lu-B2) had been implanted subcutaneously were imaged on the day of implantation and 7 days later with 3-T dynamic gadobutrol-enhanced MRI. The therapy group (n = 10) received daily administration of 10 mg/kg body weight sorafenib. Quantitative measurements of tumor perfusion, tumor vascularity, and permeability-surface area product were calculated with a two-compartment model. Dynamic contrast-enhanced MRI values were correlated with immunohistochemical results for validation. RESULTS: Tumor perfusion in sorafenib-treated prostate carcinoma declined significantly from day 0 to day 7 (47.9 ± 36.8 mL/100 mL/min to 24.4 ± 18.6 mL/100 mL/min; p < 0.05). No significant effect on permeability-surface area product was observed in either the therapy or the control group (p > 0.05). Tumor vascularity decreased significantly (p < 0.05) from day 0 to day 7 under sorafenib treatment (15.6% ± 11.4% to 5.4% ± 2.1%). Immunohistochemical analysis revealed significantly lower tumor vascularity in the therapy than in the control group (rat endothelial cell antigen 1, 74.4 ± 16.9 cells vs 197 ± 75.4 cells; p < 0.05). In sorafenib-treated tumors, significantly more apoptotic cells (terminal deoxynucleotidyl transferase-mediated nick end labeling, 6923 ± 3761 vs 3167 ± 1500; p < 0.05) and significantly fewer proliferating cells (Ki-67, 10,198 ± 3064 vs 15,003 ± 3674; p < 0.05) were observed than in the control group. Modest but significant correlations were observed between tumor perfusion and immunohistochemical tumor cell apoptosis (r = -0.56; p < 0.05) and between tumor perfusion and immunohistochemical tumor vascularity (r = 0.56; p < 0.05). CONCLUSION: Tumor perfusion quantified with gadobutrol-enhanced dynamic contrast-enhanced MRI can be used as a noninvasive surrogate parameter for monitoring the antiangiogenic, antiproliferative, and proapoptotic effects of sorafenib on prostate carcinoma allografts as validated with immunohistochemical analysis. |
| | |
Authors:
|
Clemens C Cyran; Philipp M Paprottka; Bettina Schwarz; Steven Sourbron; Michael Ingrisch; Jobst von Einem; Hubertus Pietsch; Olaf Dietrich; Rabea Hinkel; Christiane J Bruns; Maximilian F Reiser; Bernd J Wintersperger; Konstantin Nikolaou |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: AJR. American journal of roentgenology Volume: 198 ISSN: 1546-3141 ISO Abbreviation: AJR Am J Roentgenol Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7708173 Medline TA: AJR Am J Roentgenol Country: United States |
Other Details:
|
Languages: eng Pagination: 384-91 Citation Subset: AIM; IM |
Affiliation:
|
Department of Clinical Radiology, Center for Experimental Radiology, University Hospitals Munich, Campus Grosshadern, Ludwig-Maximilians-University Munich, Marchioninistrasse 15, 81377 Munich, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Histogram analysis of small solid renal masses: differentiating minimal fat angiomyolipoma from rena...
Next Document: Comparative Investigation of IV Iohexol and Iopamidol: Effect on Renal Function in Low-Risk Outpatie...